EP0057
- Generic Name
- EP0057
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- NFH8D7ZGF5
- Background
EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound camptothecin.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Ellipses Pharma
- Registration Number
- NCT05411679
- Locations
- 🇰🇷
Seoul St. Mary Hospital, Seoul, Banpo-daero 222, Banpo-dong, Seocho-gu, Korea, Republic of
🇰🇷South Korea University Hospital, Seoul, Jongno-gu, Daehak-ro, 101, Korea, Republic of
🇨🇳Changhua Christian Hospital, Changhua, No. 176, Zhonghua Rd, Taiwan
EP0057 in Combination With Olaparib in Advanced Ovarian Cancer
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Ellipses Pharma
- Target Recruit Count
- 34
- Registration Number
- NCT04669002
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
ðŸ‡ðŸ‡ºNational Institute of Oncology, Budapest, Hungary
ðŸ‡ðŸ‡ºPetz Aladár County Teaching Hospital, GyÅ‘r, Hungary
Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 136
- Registration Number
- NCT02769962
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.